期刊文献+

凯时注射液治疗糖尿病肾病的临床疗效 被引量:1

下载PDF
导出
摘要 目的观察凯时注射液(lipo PGE1)在糖尿病肾病中的疗效。方法将48例糖尿病肾病患者随机按1:1分为治疗组和对照组各24例,2组均采用非透析方法及相同的常规药物治疗,治疗组加用lipo PGE1 10μg,每日1次,共2周。结果治疗组治疗后24h尿蛋白定量明显下降,与治疗前相比差异显著(P<0.01)。对照组治疗前后24 h尿蛋白定量无显著性差异(P>0.05)。结论lipo PGE1可以减少蛋白尿,是治疗糖尿病肾病安全有效的药物之一。
作者 赖静波
出处 《西北药学杂志》 CAS 2005年第1期31-32,共2页 Northwest Pharmaceutical Journal
  • 相关文献

参考文献6

  • 1[1]The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus :Report of the Expert Committee on the Diagnosis and Classificationof Diabetes Mellitus[J]. Diabetes Care, 1997,20(7):1183-1197. 被引量:1
  • 2[2]Mogenson CE. The stages in diabetic renal disease with emphasis on thestage of incipient diabetic nephropathy [J]. Diabetes, 1993,32(Supp-2) :64-78. 被引量:1
  • 3[3]Ito S, Johnson C S, Carretero O A. Modulation of angiotensin I-induced vasoconstriction by endotheliumderived relaxing factor in the isolated microperfused rabbit afferent arteriole[J]. J Clin Invest, 1991,87(5):1656-1663. 被引量:1
  • 4[4]Anderson S, Bvenner BM. Pathogenesis of diabetic glomerulopahy: hemodynamic considerations [ J ].Diabetes Metab Rev, 1988,4(2):163-177. 被引量:1
  • 5[5]Okads S, Ichiki K, Tanokuchi S, et al. Effect of prostaglandin E1 on the renin-aldosterone system in patient with diabetic nephropathy[J]. J Int Med Res,1993,21 (3): 126-132. 被引量:1
  • 6卢爱华,胡敏.前列腺素E_1在糖尿病慢性并发症中的应用研究[J].国外医学(内分泌学分册),2000,20(3):135-137. 被引量:110

二级参考文献10

  • 1Cawello W,Leonhardt A,Schweer H,etal.Dose proportional pharmacokinetics of alpro-stadil (prostaglandin E1)in healthyvolunteers following intravenous infusion 〔J〕.Br J Clin Pharmacol,1995,40:273~276. 被引量:1
  • 2Anggard E.The biological activities of three metabolites of prostaglandin E1 〔J〕.ActaPhysiol Scand,1996,66:509~510. 被引量:1
  • 3Yasuda H,Maeda K,Sonobe M,et al.Metabolic effect of PGE1 analogue O1206.αCD onnerve Na+-K+-ATPase activity of rats with streptozotocin-induced diabetes is mediatedvia cAMP: possible role of cAMP in diabetic neuropathy 〔J〕.Prostaglandins,1994,47:367~378. 被引量:1
  • 4Okada S,Ichiki K,Tanokuchi S,et al.Effect of prostaglandin E1 on therenin-aldosterone system in patients with diabetic nephropathy 〔J〕.J Int MedRes,1993,21:126~132. 被引量:1
  • 5Young MJ, Veves A,Smith JV, et al.Restoring lower limb blood flow improvesconduction velocity in diabetic patients 〔J〕.Diabetologia,1995,38:1051~1054. 被引量:1
  • 6Partanen J,Niskanen L,Lehtinen J,et al.Natural history of peripheral neuropathy inpatients with non-insulin-dependent diabetes mellitus 〔J〕. N Engl J Med,1995,333:89~94. 被引量:1
  • 7Yasuda H,Sonobe M,Hatanaka I,et al.A new prostaglandin E1 analogue (TFC-612)prevents a decrease in motor conduction velocity in streptozocin-diabetic rats 〔J〕.BiochemBiophys Res Commun,1998,150:225~230. 被引量:1
  • 8Shindo H,Tawata M,Inoue M,et al.The effect of prostaglandin E1.αCD on vibratorythreshold determined with the SMV-5 vibrometer in patients with diabetic neuropathy 〔J〕.DiabetesRes Clin Pract,1994,24:173~180. 被引量:1
  • 9Okada S,Sato K,Higuchi T,et al.Influence of prostaglandin E1 on slight proteinuriain non-azotaemic diabetes 〔J〕.J Int Med Res,1992,20:94~97. 被引量:1
  • 10Creutzig A,Bullinger M,Cachovan M,et al.Improvement in the quality of life afteri.v.PGE1 therapy for intermittent claudication 〔J〕.Vasa,1997,26:122~127. 被引量:1

共引文献109

同被引文献29

引证文献1

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部